Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 4/20 | 0.72 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.66 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312190 | 1.00 | POLA1 (0.72) | POLA1NR1H2NR1H3PTPN1PDE4D | |
| SCHEMBL29295291 | 1.00 | POLA1 (0.72) | POLA1NR1H2NR1H3PTPN1PDE4D | |
| SCHEMBL20561120 | 1.00 | POLA1 (0.72) | POLA1NR1H2NR1H3PTPN1PDE4D | |
| SCHEMBL6309935 | 1.00 | POLA1 (0.72) | POLA1NR1H2NR1H3PTPN1PDE4D | |
| SCHEMBL6312187 | 1.00 | POLA1 (0.72) | POLA1NR1H2NR1H3PTPN1PDE4D | |
| SCHEMBL6309781 | 0.92 | NR1H2 (0.69) | POLA1NR1H2NR1H3PTPN1CYP2C9 | |
| SCHEMBL6312196 | 0.92 | NR1H2 (0.64) | POLA1NR1H2NR1H3PTPN1CYP2C9 | |
| SCHEMBL20561720 | 0.92 | NR1H2 (0.64) | POLA1NR1H2NR1H3PTPN1CYP2C9 | |
| SCHEMBL31678856 | 0.92 | NR1H2 (0.64) | POLA1NR1H2NR1H3PTPN1CYP2C9 | |
| SCHEMBL6309780 | 0.92 | NR1H2 (0.69) | POLA1NR1H2NR1H3PTPN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589101-B2 | Cyclodextrin protein drug conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20250270163-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMA (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250171622-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12209180-B2 | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists | REGENERON PHARMACEUTICALS, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240408223-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMA (US) | 2024-12-12 | — | — | US | disclosed |
| US-12134631-B2 | Hydrophilic linkers for antibody drug conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4428142-A2 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-3883926-B1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMA (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3883926-B1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMA (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| CN-111065622-A | Bis-octahydrophenanthrenecarboxamides and protein conjugates thereof | 里珍纳龙药品有限公司 | 2020-04-24 | — | — | CN | disclosed |
| CN-110944718-A | Cyclodextrin protein drug conjugates | 里珍纳龙药品有限公司 | 2020-03-31 | — | — | CN | disclosed |
| EP-3624894-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | Regeneron Pharmaceuticals, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2019217591-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019217591-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2018213077-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| US-20180334426-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-20180333504-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | REGENERON PHAMACEUTICALS, INC. | 2018-11-22 | — | — | US | disclosed |
| US-6908934-B2 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20030125357-A1 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209180-B2 | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists | NR1H3, NR1H2, NR1H4 | POLA1 2346/4885NR1H2 2/4885NR1H3 1/4885 |
| US-20030125357-A1 | Therapeutic compounds for treating dyslipidemic conditions | NR1H2, NR1H3, APOB | POLA1 3183/4885NR1H2 1/4885NR1H3 2/4885 |
| US-12589101-B2 | Cyclodextrin protein drug conjugates | SSB, CHP1, IAPP | POLA1 1696/4885NR1H2 3598/4885NR1H3 3733/4885 |
| US-20180334426-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | POLA1 2752/4885NR1H2 4/4885NR1H3 2/4885 |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | CD47, MSR1, LDLR | POLA1 2693/4885NR1H2 195/4885NR1H3 128/4885 |
| US-20180333504-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | SDCBP, DDOST, KRTCAP2 | POLA1 4011/4885NR1H2 1304/4885NR1H3 1332/4885 |
| US-20250171622-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | NR1H3, NR1H2, NR1H4 | POLA1 2346/4885NR1H2 2/4885NR1H3 1/4885 |
| US-12134631-B2 | Hydrophilic linkers for antibody drug conjugates | CD44, CD47, EPCAM | POLA1 3401/4885NR1H2 3175/4885NR1H3 2873/4885 |
| US-20250270163-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | POLA1 2752/4885NR1H2 4/4885NR1H3 2/4885 |
| US-20240408223-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | POLA1 3401/4885NR1H2 3175/4885NR1H3 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.